Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0376358 (
prostate cancer
)
59,338
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Although various mechanisms of castration-resistant
prostate cancer
(CRPC) have been discovered, reliable biomarkers for monitoring CRPC progression are lacking. We sought to identify molecules that predict the progression of advanced
prostate cancer
(AdvPC) into CRPC. The study used primary-site samples (
N
=45 for next-generation sequencing (NGS);
N
=243 for real-time polymerase chain reaction) from patients with
prostate cancer
(PC). Five public databases containing microarray data of AdvPC and CRPC samples were analyzed. The NGS data showed that each progression step in PC associated with distinct gene expression profiles.
Androgen receptor
(
AR
) associated with tumorigenesis, advanced progression, and progression into CRPC. Analysis of the paired and unpaired AdvPC and CRPC samples in the NGS cohort showed that 15 genes associated with progression into CRPC. This was validated by cohort-1 and public database analyses. Analysis of the third cohort with AdvPC showed that higher
serine peptidase inhibitor, Kazal type 1
(
SPINK1
) and lower
Sp8 transcription factor
(
SP8
) expression associated with progression into CRPC (log-rank test, both
P
<0.05). Multivariate regression analysis showed that higher
SPINK1
(Hazard Ratio (HR)=4.506, 95% confidence intervals (CI)=1.175-17.29,
P
=0.028) and lower
SP8
(HR=0.199, 95% CI=0.063-0.632,
P
=0.006) expression independently predicted progression into CRPC. Gene network analysis showed that CRPC progression may be mediated through the
AR-SPINK1
pathway by a
HNF1A
-based gene network. Taken together, our results suggest that
SPINK1
and
SP8
may be useful for classifying patients with AdvPC who have a higher risk of progressing to CRPC.
...
PMID:Transcriptomic features of primary prostate cancer and their prognostic relevance to castration-resistant prostate cancer. 2938 25